Development and multicenter validation of a cfDNA methylation-based PCR assay (myESCAP) with machine-learning prediction for non-invasive detection of esophageal cancer.
A blood-based test showed promise for detecting esophageal cancer non-invasively, though early-stage detection rates need improvement before clinical use.
This multicenter retrospective case-control diagnostic validation study examined validation of a cfDNA methylation PCR assay for non-invasive esophageal cancer detection. The assay achieved validation area under the curve near 0.82 with about 76 percent sensitivity and 89 percent specificity, although stage-one sensitivity remained limited.
What the study was
- Study design
- Multicenter retrospective case-control diagnostic validation study
- Population
- 489 esophageal cancer cases and 555 non-malignant controls
- Sample size
- 1044
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Journal of advanced research
Why it surfaced
Retained as a high-priority multicenter retrospective case-control diagnostic validation study after PubMed abstract review; the score reflects clinical relevance, design strength, novelty, and population need under the v1.3 conservative rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.